Aronora is a clinical stage biotechnology company engaged in the development of proprietary biologic therapeutics, including recombinant monoclonal antibodies and enzymes. Our rationally designed therapeutic agents are expected to reduce the progression and growth of life-threatening blood clots without the detrimental bleeding side effects that characterize all currently marketed antithrombotic drugs. The target indications include suspected or verified stroke, heart attack, pulmonary embolism, device initiated thrombosis, sepsis associated disseminated intravascular coagulation (DIC), and other thrombo-inflammatory conditions. Building on the company’s ground-breaking approaches to superior safety, Aronora’s product candidates have the potential to become first-in-class therapeutics to treat life-threatening acute thrombotic diseases.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
AB002 (E-WE thrombin)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):